A new Crohn’s treatment that involves guselkumab showed outstandingly greater rates of endoscopic improvement, which are vital for reducing long-term complications.

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with multiple different classes of medications targeting different pathways of ...

Guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed ...

University of Birmingham medical student Nikhil Mistry gained a prestigious top prize at the 2025 Dr Falk Pharma/Guts UK ...

A low-emulsifier-containing diet led to a threefold increased likelihood of improvement in symptoms of Crohn’s disease ...

Omvoh® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn’s ...

A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with mild Crohn’s disease, offering a potential pathway toward more personalized ...

Intravenous induction followed by subcutaneous maintenance therapy with guselkumab is efficacious for adults with moderately ...

In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to ...